Skip to main content
Erschienen in: Osteoporosis International 5/2003

01.09.2003 | Editorial

Bone quality: an old concept revisited

verfasst von: Mary L. Bouxsein

Erschienen in: Osteoporosis International | Sonderheft 5/2003

Einloggen, um Zugang zu erhalten

Excerpt

Quality
a)
an inherent or distinguishing characteristic; a property
 
b)
essential character; nature
 
c)
superiority of kind; degree or grade of excellence
 
Literatur
1.
Zurück zum Zitat NIA Workshop on Aging and Bone Quality. Calcif Tissue Int 53:S1–S180 NIA Workshop on Aging and Bone Quality. Calcif Tissue Int 53:S1–S180
2.
Zurück zum Zitat Sherman S, Hadley E (1993) Aging and bone quality: an underexplored frontier. Calcif Tissue Int 53:S1 Sherman S, Hadley E (1993) Aging and bone quality: an underexplored frontier. Calcif Tissue Int 53:S1
3.
Zurück zum Zitat NIH Consensus Development Panel (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795PubMed NIH Consensus Development Panel (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795PubMed
4.
Zurück zum Zitat Miller PD, Siris ES, Barrett-Connor E, et al (2002) Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res 17:2222–2230PubMed Miller PD, Siris ES, Barrett-Connor E, et al (2002) Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res 17:2222–2230PubMed
5.
Zurück zum Zitat Wainwright S, Phipps K, Stone J, et al (2001) A large proportion of fractures in postmenopausal women occur with baseline bone mineral density T-score >−2.5. J Bone Miner Res 16:S155 Wainwright S, Phipps K, Stone J, et al (2001) A large proportion of fractures in postmenopausal women occur with baseline bone mineral density T-score >−2.5. J Bone Miner Res 16:S155
6.
Zurück zum Zitat Haguenauer D, Welch V, Shea B, et al (2000) Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int 11:727–738CrossRefPubMed Haguenauer D, Welch V, Shea B, et al (2000) Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int 11:727–738CrossRefPubMed
7.
Zurück zum Zitat Cranney A, Wells G, Willan A, et al (2002) Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508–516CrossRefPubMed Cranney A, Wells G, Willan A, et al (2002) Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508–516CrossRefPubMed
8.
Zurück zum Zitat Cranney A, Tugwell P, Adachi J, et al (2002) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517–523CrossRefPubMed Cranney A, Tugwell P, Adachi J, et al (2002) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517–523CrossRefPubMed
9.
Zurück zum Zitat Cranney A, Tugwell P, Zytaruk N, et al (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 23:524–528CrossRefPubMed Cranney A, Tugwell P, Zytaruk N, et al (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 23:524–528CrossRefPubMed
10.
Zurück zum Zitat Cummings SR, Karpf DB, Harris F, et al (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281–289CrossRefPubMed Cummings SR, Karpf DB, Harris F, et al (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281–289CrossRefPubMed
11.
Zurück zum Zitat Sarkar S, Mitlak BH, Wong M, et al (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1–10PubMed Sarkar S, Mitlak BH, Wong M, et al (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1–10PubMed
12.
Zurück zum Zitat Pols HA, Felsenberg D, Hanley DA, et al (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461–468CrossRefPubMed Pols HA, Felsenberg D, Hanley DA, et al (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461–468CrossRefPubMed
13.
Zurück zum Zitat Black DM, Cummings SR, Karpf DB, et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group [see comments]. Lancet 348:1535–1541PubMed Black DM, Cummings SR, Karpf DB, et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group [see comments]. Lancet 348:1535–1541PubMed
14.
Zurück zum Zitat Watts NB, Josse RG, Hamdy RC, et al (2003) Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 88:542–549CrossRefPubMed Watts NB, Josse RG, Hamdy RC, et al (2003) Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 88:542–549CrossRefPubMed
15.
Zurück zum Zitat Harris ST, Watts NB, Genant HK, et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352PubMed Harris ST, Watts NB, Genant HK, et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352PubMed
16.
Zurück zum Zitat van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787CrossRef van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787CrossRef
Metadaten
Titel
Bone quality: an old concept revisited
verfasst von
Mary L. Bouxsein
Publikationsdatum
01.09.2003
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe Sonderheft 5/2003
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-003-1467-3

Weitere Artikel der Sonderheft 5/2003

Osteoporosis International 5/2003 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.